745 Views | 396 Downloads
Edward Faught, Emory University, Brain Health Center 292, 12 Executive Park Drive NE, Atlanta, GA 30329, U.S.A. E‐mail: rfaught@emory.edu
The authors acknowledge the contributions of David Rudd to this analysis.
The authors thank the subjects and their caregivers in addition to the investigators and their teams who contributed to this study.
The authors acknowledge Jesse Fishman, PharmD, of UCB Pharma (Atlanta, Georgia, U.S.A.) for publication coordination.
Editorial support was provided by Richard Fay and Lynne Isbell of Evidence Scientific Solutions (Philadelphia, Pennsylvania, U.S.A.) and was funded by UCB Pharma.
Jacquelyn Bainbridge has received honoraria for service on advisory boards from Sunovion and UCB Pharma, investigator‐initiated grant funding from Supernus and UCB Pharma, and grant support from NINDS.
Marc De Backer, Klaus Eckhardt, Frank Tennigkeit, Sabine Bongardt, and Konrad J. Werhahn are all employees of UCB Pharma.
David Sen was an employee of UCB Pharma at the time of the study.
Aziz Shaibani has no conflict of interest to disclose.
Edward Faught has received consulting fees from Eisai, SAGE, Sunovion, UCB, and Upsher‐Smith and for service on Data Safety Monitoring Boards from Eisai, Lundbeck, and SK Life Science.
Edward Faught has received research support from Brain Sentinel and UCB.
We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guideline.
This study was a UCB Pharma–sponsored study.
© 2017 The Authors. Epilepsia Open published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy.